Circulating Tumour DNA (ctDNA) in Patients With Colorectal Cancer and the Relationship to Imaging Features of Extramural Venous Invasion
Recruiting · NCT02579278 · Observational (researchers observe without assigning treatment) · Lead sponsor: Imperial College London
View the official record on ClinicalTrials.gov →Interventions studied
Blood sample (mrEMVI negative patient)Blood sample (mrEMVI positive patient)
What this trial is about
This study does not involve randomization or treatment. Eligible patients have colorectal adenocarcinoma with no metastases eligible for curative surgery. A pre operative staging scan must have been completed within 6 weeks prior to surgery. Two x 20ml blood samples will be taken from each patient, one prior to and one during or within 24hrs after surgery. Patients are annually followed up to 3 years.
Who can take part
Age range
16 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Have a biopsy-confirmed colorectal adenocarcinoma
- Is eligible for curative surgery
- Has no metastatic disease on CT scan
- Has completed pre-operative staging scan within six weeks prior to surgery
- Have provided written informed consent to participate in the study
- Be aged 16 years or over
Exclusion criteria
- Have metastatic disease (including resectable liver metastases)
- Have a synchronous second malignancy
- Are contraindicated for any imaging able to determine EMVI status
Where it is running
3 locations listed.
- Queen Elizabeth the Queen Mother Hospital - Margate, Kent, United Kingdom
- St Mary's Hospital (Imperial) - Hammersmith, London, United Kingdom
- Royal Marsden Hospital NHS Foundation Trust - Sutton, Surrey, United Kingdom